Targeting the NLRP3 Inflammasome Via BTK

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2021 Mar 15

PMID 33718366

Citations 21

Authors

Alexander N R Weber

Affiliations

Soon will be listed here.

Abstract

The NLRP3 inflammasome represents a critical inflammatory machinery driving pathology in many acute (e. g., myocardial infarction or stroke) and chronic (Alzheimer's disease, atherosclerosis) human disorders linked to the activity of IL-1 cytokines. Although the therapeutic potential of NLRP3 is undisputed, currently no clinically approved therapies exist to target the NLRP3 inflammasome directly. The recent discovery of BTK as a direct and positive regulator of the NLRP3 inflammasome has, however, raised the intriguing possibility of targeting the NLRP3 inflammasome via existing or future BTK inhibitors. Here, I review the mechanistic basis for this notion and discuss the molecular and cellular role of BTK in the inflammasome process. Specific attention will be given to cell-type dependent characteristics and differences that may be relevant for targeting approaches. Furthermore, I review recent (pre-)clinical evidence for effects of BTK inhibitors on NLRP3 activity and highlight and discuss open questions and future research directions. Collectively, the concept of targeting BTK to target NLRP3-dependent inflammation will be explored comprehensively at the molecular, cellular and therapeutic levels.

Citing Articles

The Immunomodulatory Mechanisms of BTK Inhibition in CLL and Beyond.

Jiang Q, Peng Y, Herling C, Herling M Cancers (Basel). 2024; 16(21).

PMID: 39518015 PMC: 11545099. DOI: 10.3390/cancers16213574.

Fenebrutinib, a Bruton's tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways.

Langlois J, Lange S, Ebeling M, Macnair W, Schmucki R, Li C J Neuroinflammation. 2024; 21(1):276.

PMID: 39465429 PMC: 11514909. DOI: 10.1186/s12974-024-03267-5.

NLRP3 Inflammasome's Activation in Acute and Chronic Brain Diseases-An Update on Pathogenetic Mechanisms and Therapeutic Perspectives with Respect to Other Inflammasomes.

Chiarini A, Gui L, Viviani C, Armato U, Dal Pra I Biomedicines. 2023; 11(4).

PMID: 37189617 PMC: 10135565. DOI: 10.3390/biomedicines11040999.

Inflammation and Epstein-Barr Virus at the Crossroads of Multiple Sclerosis and Post-Acute Sequelae of COVID-19 Infection.

Rousseau B, Bhaduri-McIntosh S Viruses. 2023; 15(4).

PMID: 37112929 PMC: 10141000. DOI: 10.3390/v15040949.

Bruton's tyrosine kinase inhibition attenuates disease progression by reducing renal immune cell invasion in mice with hemolytic-uremic syndrome.

Kroller S, Wissuwa B, Dennhardt S, Krieg N, Thiemermann C, Daniel C Front Immunol. 2023; 14:1105181.

PMID: 36911665 PMC: 9995712. DOI: 10.3389/fimmu.2023.1105181.

References

Purvis G, Collino M, Aranda-Tavio H, Chiazza F, ORiordan C, Zeboudj L . Inhibition of Bruton's TK regulates macrophage NF-κB and NLRP3 inflammasome activation in metabolic inflammation. Br J Pharmacol. 2020; 177(19):4416-4432. PMC: 7484557. DOI: 10.1111/bph.15182. View

Jaglowski S, Blazar B . How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. Blood Adv. 2018; 2(15):2012-2019. PMC: 6093735. DOI: 10.1182/bloodadvances.2018013060. View

Takeuchi O, Akira S . Pattern recognition receptors and inflammation. Cell. 2010; 140(6):805-20. DOI: 10.1016/j.cell.2010.01.022. View

Munoz-Planillo R, Kuffa P, Martinez-Colon G, Smith B, Rajendiran T, Nunez G . K⁺ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity. 2013; 38(6):1142-53. PMC: 3730833. DOI: 10.1016/j.immuni.2013.05.016. View

Byrd J, Furman R, Coutre S, Flinn I, Burger J, Blum K . Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369(1):32-42. PMC: 3772525. DOI: 10.1056/NEJMoa1215637. View

Wilson W, Young R, Schmitz R, Yang Y, Pittaluga S, Wright G . Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015; 21(8):922-6. PMC: 8372245. DOI: 10.1038/nm.3884. View

Strijbis K, Tafesse F, Fairn G, Witte M, Dougan S, Watson N . Bruton's Tyrosine Kinase (BTK) and Vav1 contribute to Dectin1-dependent phagocytosis of Candida albicans in macrophages. PLoS Pathog. 2013; 9(6):e1003446. PMC: 3694848. DOI: 10.1371/journal.ppat.1003446. View

Weber A, Bittner Z, Liu X, Dang T, Radsak M, Brunner C . Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity. Front Immunol. 2017; 8:1454. PMC: 5682317. DOI: 10.3389/fimmu.2017.01454. View

Kondo K, Shaim H, Thompson P, Burger J, Keating M, Estrov Z . Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia. 2017; 32(4):960-970. PMC: 6128536. DOI: 10.1038/leu.2017.304. View

10.

Bittner Z, Liu X, Mateo Tortola M, Tapia-Abellan A, Shankar S, Andreeva L . BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity. J Exp Med. 2021; 218(11). PMC: 8480672. DOI: 10.1084/jem.20201656. View

11.

McNally G, Long J, Brophy L, Badillo M . Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia. J Adv Pract Oncol. 2016; 6(5):420-31. PMC: 4803460. DOI: 10.6004/jadpro.2015.6.5.3. View

12.

Dempsey C, Rubio Araiz A, Bryson K, Finucane O, Larkin C, Mills E . Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice. Brain Behav Immun. 2016; 61:306-316. DOI: 10.1016/j.bbi.2016.12.014. View

13.

Masters S, Dunne A, Subramanian S, Hull R, Tannahill G, Sharp F . Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol. 2010; 11(10):897-904. PMC: 3103663. DOI: 10.1038/ni.1935. View

14.

Wree A, Eguchi A, McGeough M, Pena C, Johnson C, Canbay A . NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology. 2013; 59(3):898-910. PMC: 4008151. DOI: 10.1002/hep.26592. View

15.

Weber A, Bittner Z, Shankar S, Liu X, Chang T, Jin T . Recent insights into the regulatory networks of NLRP3 inflammasome activation. J Cell Sci. 2020; 133(23). DOI: 10.1242/jcs.248344. View

16.

Jongstra-Bilen J, Cano A, Hasija M, Xiao H, Smith C, Cybulsky M . Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis. J Immunol. 2008; 181(1):288-98. DOI: 10.4049/jimmunol.181.1.288. View

17.

Hu S, Peng L, Kwak Y, Tekippe E, Pasare C, Malter J . The DNA Sensor AIM2 Maintains Intestinal Homeostasis via Regulation of Epithelial Antimicrobial Host Defense. Cell Rep. 2015; 13(9):1922-36. PMC: 5477202. DOI: 10.1016/j.celrep.2015.10.040. View

18.

Liu X, Pichulik T, Wolz O, Dang T, Stutz A, Dillen C . Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. J Allergy Clin Immunol. 2017; 140(4):1054-1067.e10. DOI: 10.1016/j.jaci.2017.01.017. View

19.

ORiordan C, Purvis G, Collotta D, Krieg N, Wissuwa B, Sheikh M . X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure. Front Immunol. 2020; 11:581758. PMC: 7580254. DOI: 10.3389/fimmu.2020.581758. View

20.

Yanaba K, Yoshizaki A, Asano Y, Kadono T, Tedder T, Sato S . IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am J Pathol. 2011; 178(2):735-43. PMC: 3069829. DOI: 10.1016/j.ajpath.2010.10.022. View